Effect of tiotropium on COPD exacerbations: A systematic review (Q26750751)

2

object named as

Claus Vogelmeier

0 references

author name string

David M G Halpin

1

0 references

Michael P Pieper

3

0 references

Norbert Metzdorf

4

0 references

Frank Richard

Novel insights into M3 muscarinic acetylcholine receptor physiology and structure

5

0 references

language of work or name

English

0 references

publication date

May 2016

0 references

published in

Respiratory Medicine

0 references

volume

114

0 references

page(s)

1-8

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

A one-year trial of tiotropium Respimat plus usual therapy in COPD patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Premature discontinuation during the UPLIFT study

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Molecular basis for the long duration of action and kinetic selectivity of tiotropium for the muscarinic M3 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

A 4-year trial of tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Tiotropium Respimat inhaler and the risk of death in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

COPD exacerbations: definitions and classifications.

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

The burden of illness and economic evaluation for COPD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Impact of preventing exacerbations on deterioration of health status in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

The effect of tiotropium on exacerbations and airflow in patients with COPD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD.

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Pharmacologic rationale underlying the therapeutic effects of tiotropium/olodaterol in COPD

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021

Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.RMED.2016.02.012

7 January 2021